Two novel dual-modal MRI/optical probes based on a rhodamine-DO3A conjugate have been prepared. The bis(aqua)gadolinium(III) complex Gd.L1 and mono(aqua)gadolinium(III) complex Gd.L2 behave as dual-modal imaging probes (r1 = 8.5 and 3.8 mM(-1) s(-1) for Gd.L1 and Gd.L2, respectively; λex = 560 nm and λem = 580 nm for both complexes). The rhodamine fragment is pH-sensitive, and upon lowering of the pH, an increase in fluorescence intensity is observed as the spirolactam ring opens to give the highly fluorescent form of the molecule. The ligands are bimodal when coordinated to Tb(III) ions, inducing fluorescence from both the lanthanide center and the rhodamine fluorophore, on two independent time frames. Confocal imaging experiments were carried out to establish the localization of Gd.L2 in HEK293 cells and primary mouse islet cells (∼70% insulin-containing β cells). Colocalization with MitoTracker Green demonstrated Gd.L2's ability to distinguish between tumor and healthy cells, with compartmentalization believed to be in the mitochondria. Gd.L2 was also evaluated as an MRI probe for imaging of tumors in BALB/c nude mice bearing M21 xenografts. A 36.5% decrease in T1 within the tumor was observed 30 min post injection, showing that Gd.L2 is preferentially up taken in the tumor. Gd.L2 is the first small-molecule MR/fluorescent dual-modal imaging agent to display an off-on pH switch upon its preferential uptake within the more acidic microenvironment of tumor cells.
Two novel dual-modal MRI/optical probes based on a rhodamine-DO3A conjugate have been prepared. The bis(aqua)gadolinium(III) complex Gd.L1 and mono(aqua)gadolinium(III) complex Gd.L2 behave as dual-modal imaging probes (r1 = 8.5 and 3.8 mM(-1) s(-1) for Gd.L1 and Gd.L2, respectively; λex = 560 nm and λem = 580 nm for both complexes). The rhodamine fragment is pH-sensitive, and upon lowering of the pH, an increase in fluorescence intensity is observed as the spirolactam ring opens to give the highly fluorescent form of the molecule. The ligands are bimodal when coordinated to Tb(III) ions, inducing fluorescence from both the lanthanide center and the rhodamine fluorophore, on two independent time frames. Confocal imaging experiments were carried out to establish the localization of Gd.L2 in HEK293 cells and primary mouse islet cells (∼70% insulin-containing β cells). Colocalization with MitoTracker Green demonstrated Gd.L2's ability to distinguish between tumor and healthy cells, with compartmentalization believed to be in the mitochondria. Gd.L2 was also evaluated as an MRI probe for imaging of tumors in BALB/c nude mice bearing M21 xenografts. A 36.5% decrease in T1 within the tumor was observed 30 min post injection, showing that Gd.L2 is preferentially up taken in the tumor. Gd.L2 is the first small-molecule MR/fluorescent dual-modal imaging agent to display an off-on pH switch upon its preferential uptake within the more acidic microenvironment of tumor cells.
Molecular imaging is
a rapidly growing
area of chemistry that aims
to visualize cellular function and structure in a noninvasive manner
with the in vivo use of specially designed imaging agents. The combination
of magnetic resonance imaging (MRI) and optical imaging offers synergistic
advantages over either modality alone. MRI has high spatial resolution
and good soft-tissue contrast[1,2] while optical imaging
displays high sensitivity and can give information on the local chemical
environment.[3] Lanthanide-based optical
probes have superior fluorescence properties in comparison to organic
fluorophores, with luminescence lifetimes stretching to the millisecond
region, and time-gated techniques can be employed in order to eliminate
interfering background autofluorescence.[4−6]With the constant
advances in cancer treatment, it is becoming
increasingly important to detect the early signs of the disease and
to establish the efficacy of the concurrent treatment in a noninvasive
manner. This can be achieved by the in vivo use of a dual-modal MRI/fluorescent
probe that responds to a characteristic trait of tumor cells.[7−9] It is known that the mitochondrial potential in cancer cells is
greater than that of healthy cells,[10] and
the design of a probe that can accumulate in these energized mitochondria
will lead to a tumor-targeting agent. The combination of MRI and fluorescence
will allow for improved diagnostic accuracy by tumor localization
via MRI imaging and guided surgery via fluorescence imaging.MRI is a noninvasive diagnostic technique that relies on the enhancement
of local water proton relaxation.[11,12] Different
tissues have different relaxation times, resulting in endogenous magnetic
resonance contrast. Exogenous agents can be used to enhance this contrast
by selectively shortening the T1 (longitudinal)
or T2 (transverse) relaxation time; these
agents include Gd(III) chelates, manganese complexes, and superparamagnetic
nanoparticles.[13,14] The most successful and commonly
used of these exogenous agents are complexes containing the Gd(III)
ion because of its high magnetic moment (7.9μB) given
by its seven unpaired electrons and its totally symmetric electronic
ground state (8S7/2).[15] According to Solomon–Bloembergen–Morgan theory, the
relaxivity of Gd(III) complexes is governed by a number of factors,
including the number of bound water molecules (q),
the rotational tumbling time (rotational correlation time) of the
complex (τR), and the mean residence lifetime of
Gd(III)-bound water molecules (τM).[2] An effective way to increase the relaxivity of a Gd(III)
complex is to increase the number of bound water molecules. Herein
we report two novel probes possessing different hydration states.
We envisioned that the relaxivity could be improved by decreasing
the number of coordination sites on the Gd(III) chelate from eight
to seven, allowing for a change from one bound water molecule to two.
It is reported however that heptadentate ligands, when bound to Gd(III),
have unfavorable properties for use as MRI probes in terms of thermodynamic
and kinetic stability because of the coordinatively unsaturated nature
of the complex.[17]Eu(III) and Tb(III)
chelates based on a DO3A core have received
a lot of interest as luminescent lanthanide systems.[18−21] These lanthanides are characterized by their long-lived luminescent
excited states (ms time scale) and linelike emission spectra, and
their complexes have been shown to be useful in biomedicine as luminescent
probes.[22] Lanthanidemetals or ions however,
have low absorption coefficients due to Laporte-forbidden f–f
transitions.[23] This can be overcome by
attaching an aromatic chromophore to the macrocyclic core to act as
an “antenna” by transferring absorbed excitation energy
from its triplet excited state to the excited state of the coordinated
lanthanide ion.[24] Rhodamine derivatives
have received significant attention as fluorescent labeling agents
because of their long absorption and emission wavelengths, large absorption
coefficients, and high quantum yields.[25] They have been used in a wide range of applications, having great
success as chemosensors (both in vitro and in vivo),[26,27] protein labels,[28] and dual-modal imaging
agents.[29,30] Rhodamine derivatives have had particular
success as mitochondria targets,[31−33] as their delocalized
organic cationic forms tend to accumulate in the mitochondria of tumor
cells as a result of the increased negative mitochondrial potential.[34−36] The spiro ring-opening mechanism of rhodamine has also led to its
extensive use as a chemosensor for metal detection as well as a pH-sensitive
probe.[37−39] Under acidic conditions, the rhodamine moiety exists
in its highly fluorescent pink-colored open form. Upon addition of
OH–, the structure exists in its spirocyclic form,
which is colorless and nonfluorescent.In recent years there
have been an increasing number of reports
of multimodal imaging probes wherein two or more imaging modalities
are combined.[40,41] The combination of modalities
leads to probes that give enhanced visualization and improved reliability
of data by synergistically combining imaging techniques to overcome
their inherent disadvantages. MRI gives high anatomical resolution
and deep tissue penetration but lacks sensitivity. Optical imaging,
however, boasts high sensitivity but has limited tissue penetration.
As discussed earlier, the combination of the two techniques yields
a probe that is able to provide a more complete picture of the biological
area of interest. There are few reports of dual-modal MRI/optical
imaging agents in the literature that are not of nanoparticle nature.
These include Gou et al.’s description of the binding of a
cyanine–DTPA conjugate to BSA to afford relaxivity rate constants
of 15 mM–1 s–1.[42] The aliphatic nature of the chelate is unfavorable, however,
as release of Gd(III) ions into the body from these types of complexes
has been related to nephrogenic systemic fibrosis (NSF).[43] In 1998, it was reported that a rhodamine–Gd(III)
complex conjugate showed no MRI contrast enhancement when introduced
to Xenopus laevis embryos.[44] The same complex conjugate, Gd(Rhoda-DOTA),
was studied alongside a series of hydrophobic fluorescent dye–Gd(III)
complex conjugates in 2011 by Yamane et al.,[45] who found that incorporation of the hydrophobic fluorescent moiety
improves cell permeability compared to Gd(DOTA). They reported that
Gd(Rhoda-DOTA) showed a large increase in r1 relaxivity when bound to albumin and efficient cell permeation when
incubated with HeLa cells. Again, however, no significant change in
the MR signal of HeLa cells was observed in the presence of the complex,
even though its fluorescence was observed by microscopy. Similarly,
a rhodamine moiety has previously been conjugated to DO3A and consequently
labeled with 64Cu to arrive at a dual-modal PET/optical
probe.[30] It was found that 64Cu(DOTA-LRB) had a surprisingly high tumor uptake compared with other 64Cu-labeled organic cations. The probe was able to selectively
localize to the tumor mitochondria with long tumor retention times.[46] The probe and its derivatives have been the
subjects of extensive in vitro and in vivo studies showing that there
is promise for a Gd(III) MRI/optical analogue to be as successful
in vivo.In this paper, we report two novel methods for conjugating
fluorescent
rhodamine derivatives to DO3A. We evaluated the two rhodamine–DO3AGd(III) derivatives as multimodal MRI/optical imaging agents by measuring
their relaxivity and fluorescence properties as well as their in vitro
tumor cellular localization. The Tb(III) analogues were synthesized
to assess their dual-luminescence properties, and it was found that
the organic and metal-based luminescence can be separated on different
time scales.
Results and Discussion
Synthesis
Two
new synthetic routes were developed to
obtain L1 and L2 (outlined in Schemes 1 and 2, respectively), both
commencing from commercially available rhodamine B and involving five
straightforward steps. Reaction of the carboxylic acid moiety on rhodamine
B with bromoethylamine resulted in amide bond formation, giving product 2. The ligand precursor 3 was prepared by N-alkylation
of the tri-tert-butyl ester derivative of cyclen
(tri-t-Bu-DO3A). Removal of the tert-butyl ester groups was then carried out using trifluoroacetic acid
(TFA) to obtain L1. The successful isolation of the product
was confirmed through 1H and 13C NMR spectroscopy
along with high-resolution mass spectrometry. L1 was
coordinated to a series of lanthanidemetal chloride salts [Ln = Gd(III),
Tb(III)] in water in a mildly acidic environment (pH ∼5.5).
After purification, the absence of free lanthanide ions was verified
by the use of xylenol orange indicator solution.[47] For each complex, a peak corresponding to the molecular
ion with the correct isotopic pattern could be observed by high-resolution
electrospray ionization mass spectrometry. The Ln.L1 complexes
were found to be only partially water-soluble and therefore unsuitable
for in vivo applications. Thus, the second ligand L2 was
developed to overcome the solubility issues of L1 in
water. The synthesis of L2 was very similar to that of L1. Two subsequent amide bond formation reactions on rhodamine
B were carried out, first with ethylenediamine to form 4 and then with chloroacetyl chloride resulting in product 5. This was then conjugated to tri-t-Bu-DO3A to give 6 in 39% yield, and subsequent deprotection with TFA gave L2 in the same manner as for L1. The second amide
bond was introduced to increase the hydrogen-bond donor and acceptor
ability and thereby to increase the water solubility. L2 was complexed with Gd(III) and Tb(III) as above, and the complexes Ln.L2 were found to be water-soluble.
Scheme 1
Synthesis of L1 and Ln.L1 (Ln = Gd, Tb)
Reagents and conditions: (a)
(i) POCl3, reflux, 18 h; (ii) bromoethylamine, CH3CN, room temperature, 24 h. (b) Tri-t-Bu-DO3A, K2CO3, CH3CN, reflux, 24 h. (c) TFA, DCM,
room temperature, 16 h. (d) LnCl3·6H2O,
H2O, NaOH(aq), pH 5.5, room temperature, 24 h.
Scheme 2
Synthesis of L2 and Ln.L2 (Ln = Gd, Tb)
Reagents and conditions: (a)
Ethylenediamine, EtOH, reflux, 24 h. (b) Chloroacetyl chloride, NEt3, DCM, room temperature, 2 h. (c) Tri-t-Bu-DO3A,
K2CO3, CH3CN, reflux, 24 h. (d) TFA,
DCM, room temperature, 16 h. (e) LnCl3·6H2O, H2O, NaOH(aq), pH 5.5, room temperature, 24 h.
Synthesis of L1 and Ln.L1 (Ln = Gd, Tb)
Reagents and conditions: (a)
(i) POCl3, reflux, 18 h; (ii) bromoethylamine, CH3CN, room temperature, 24 h. (b) Tri-t-Bu-DO3A, K2CO3, CH3CN, reflux, 24 h. (c) TFA, DCM,
room temperature, 16 h. (d) LnCl3·6H2O,
H2O, NaOH(aq), pH 5.5, room temperature, 24 h.
Synthesis of L2 and Ln.L2 (Ln = Gd, Tb)
Reagents and conditions: (a)
Ethylenediamine, EtOH, reflux, 24 h. (b) Chloroacetyl chloride, NEt3, DCM, room temperature, 2 h. (c) Tri-t-Bu-DO3A,
K2CO3, CH3CN, reflux, 24 h. (d) TFA,
DCM, room temperature, 16 h. (e) LnCl3·6H2O, H2O, NaOH(aq), pH 5.5, room temperature, 24 h.
Photophysical Properties
Complexes Ln.L1 and Ln.L2 (Figure 1) behave
as dual-modal MRI/optical imaging probes with Gd(III) and dual-luminescent
probes with Tb(III). In this section, we discuss the photophysical
properties of both systems. The photophysics of the two ligands with
Gd(III) were found to be very similar, as they exhibited fluorescence
emission at 580 nm upon excitation at 560 nm. This short Stokes shift
and orange fluorescence was expected, as the fluorescence properties
of rhodamine and its derivatives have been extensively studied.[48] Modification of the carboxylic acid moiety of
rhodamine B does not lead to significant changes in the photophysical
properties of the chromophore, as no electronic or structural changes
occur on the xanthene core, so a very small bathochromic shift is
observed (rhodamine B: λex = 553 nm, λem = 572 nm in ethanol).
Figure 1
Structures of Ln.L1 and Ln.L2 [Ln = Gd(III),
Tb(III)].
Structures of Ln.L1 and Ln.L2 [Ln = Gd(III),
Tb(III)].The photophysical properties of
the Tb(III) analogues were investigated
(Figure 2). Under excitation at λex = 310 nm, complex Tb.L1 displays exclusively
green emission arising from 5D4–7F transitions of terbium. The
rhodamine-centered emission is of a very low intensity in comparison
with the Tb(III) emission, indicating efficient ligand-to-lanthanide
energy transfer. At λex = 560 nm, emission is seen
at 580 nm, featuring fluorescence from the xanthene core. Therefore,
two fluorescence pathways are available to Tb.L1: emission
via the lanthanide with energy transfer from rhodamine and direct
excitation of the xanthene core. Conversely, under excitation at λex = 310 nm, the emission spectrum of complex Tb.L2 is dominated by rhodamine emission at 580 nm. Applying a 0.1 ms
delay to the fluorescence measurement allowed for isolation of the
short-lived organic fluorescence of the rhodamine moiety from the
long-lived lanthanide luminescence in both complexes. The extra amide
bond in L2 renders the complex water-soluble but also
introduces a quenching pathway. The additional N–H bond is
close to the lanthanide center, and fluorescence deactivation may
occur via the N–H vibrational energy level oscillator.[49]
Figure 2
Fluorescence
emission pathways in Tb.L1 and Tb.L2.
Therefore, when complexed with a luminescent
lanthanide ion, both
ligands behave as dual-luminescent probes. In both Tb.L1 and Tb.L2, excitation at 560 nm leads to emission from
the organic chromophore at 580 nm, with the fluorescence originating
from the xanthene core. Using time-gating techniques, Tb(III) emission
is induced in both complexes upon excitation of the isolated phenyl
ring of the rhodamine moiety at 310 nm by energy transfer to the Tb(III)metal center (Figures 2 and 3). In Tb.L1 only,
Tb(III) emission can be seen upon excititation at 310 nm without the
use of a time delay. The quantum yields of both terbium complexes
were determined, and the results were in agreement with the observed
spectra, confirming the efficient energy transfer to the terbiummetal
center in Tb.L1 (Φ = 18.6%) and the inefficient
energy transfer in Tb.L2 (Φ = 0.8%).
Figure 3
Left panel: excitation spectrum (left) and emission
spectrum (right)
of Gd.L2 with λem = 580 nm and λex = 560 nm (0 ms delay). These are also representative spectra
of Gd.L1. Right panel: absorption spectrum (left), terbium
emission (center), and rhodamine fluorescence (right) of Tb.L2 with λem = 545 nm and λex = 310
and 560 nm, respectively (0.1 ms delay for terbium emission). These
are also representative spectra of Tb.L1, although no
delay was needed to observe the terbium emission. All of the Ln.L1 complex measurements were carried out in methanol, and
all of the Ln.L2 complex measurements were carried out
in H2O (pH 7.4, 298 K, 100 μM concentration).
Fluorescence
emission pathways in Tb.L1 and Tb.L2.Left panel: excitation spectrum (left) and emission
spectrum (right)
of Gd.L2 with λem = 580 nm and λex = 560 nm (0 ms delay). These are also representative spectra
of Gd.L1. Right panel: absorption spectrum (left), terbium
emission (center), and rhodamine fluorescence (right) of Tb.L2 with λem = 545 nm and λex = 310
and 560 nm, respectively (0.1 ms delay for terbium emission). These
are also representative spectra of Tb.L1, although no
delay was needed to observe the terbium emission. All of the Ln.L1 complex measurements were carried out in methanol, and
all of the Ln.L2 complex measurements were carried out
in H2O (pH 7.4, 298 K, 100 μM concentration).The luminescence decays of the
Tb(III) complexes in both H2O and D2O were also
measured (see the Supporting Information). The luminescence lifetimes
in D2O were increased in comparison to H2O because
less nonradiative deactivation was induced by O–D vibrations
than by O–H vibrations.[50] From these
differences in the rates of energy transfer to H2O and
D2O oscillators, the hydration state can be calculated
using eq 1, in which the term 0.06 reflects
the quenching effect of unbound water molecules and n is the number of coordinated secondary amide groups, reflecting
the quenching effect of the proximate NH oscillators.[51] The emission decays were fitted to monoexponential decays,
and the corresponding lifetime measurements of both terbium complexes
confirmed the expected coordination numbers of seven for Tb.L1 and eight for Tb.L2 (Table 1).
Table 1
Selected Photophysical Data for Complexes Tb.L1 and Tb.L2
complex
τH2O/ms
τD2O/ms
q
ϕem/%
Tb.L1
1.23
2.53
1.8
18.6
Tb.L2
1.55
2.05
0.8
0.8
Relaxometric Studies
T1 measurements of the Gd(III) complexes were performed
at 400 MHz
(9.4 T, 25 °C), and their r1 values
were determined. The r1 values of 8.5
and 3.8 mM–1 s–1 obtained for
complexes Gd.L1 and Gd.L2, respectively,
were within the range for Gd(III) chelates with hydration states of
two and one respectively. These hydration states were confirmed by
the lifetime measurements of the terbium analogues.It is well-known
that the presence of hydrophobic moieties within a probe is one of
the basic structural requirements for ligand binding to human serum
albumin (HSA).[52] HSA is the most abundant
protein in blood, and binding to it results in an increase in intravascular
retention and relaxivity (due to a decrease in τR of the complex).[53] In view of the fact
that the rhodamine moiety has extended aromatic rings and hence hydrophobicity,
a study was carried out to investigate possible interactions between Gd.L2 and HSA. The relaxation rates of a series of solutions
of Gd.L2 with increasing concentrations of HSA were measured.
The relaxation rate was found to remain constant across the series
(Figure 4), therefore indicating that there
is no significant binding of the probe to the protein. The binding
mechanisms of rhodamine B with bovineserum albumin (BSA) were previously
investigated, and site-selective binding was observed. However, these
results were obtained using high molar ratios of rhodamine B to BSA
(>50).[54] Such high concentrations are
not
practical for use of MRI probes in vivo, and indeed, large changes
in relaxivity have been observed in cases where the molar ratio of
probe to serum albumin have been much lower.[55,56] It is hypothesized that the steric bulk of the complex is unsuitable
for selective binding to HSA.
Figure 4
Titration of Gd.L2 with HSA.
Titration of Gd.L2 with HSA.
pH Titration
As
previously discussed (vide supra),
the lactam ring of rhodamine can be intramolecularly opened and closed
via changes in pH.[37] The pH sensitivity
of Gd.L2 was investigated, and to show the sensitivity
of the proton-triggered ring opening, a pH titration was carried out
wherein the emission intensity was monitored at various pH values
(Figure 5). The pH titration showed that Gd.L2, which was nonfluorescent at pH 6.5 or above, rearranged
into its fluorescent form at acidic pH. The fluorescence of Gd.L2 at pH 4.3 was 50-fold brighter than that at pH 6.5 and
15-fold brighter than that at pH 6.0, demonstrating that Gd.L2 is a sensitive, acid-responsive probe capable of sensing small changes
in pH in the range 4–7.
Figure 5
Upper panel: pH-mediated ring opening
of the intramolecular sprirolactam
of Gd.L2, yielding a highly fluorescent species. Lower
panels: (a) pH-dependent emission spectra of Gd.L2 (λex = 560 nm, λem = 580 nm); (b) pH titration
curve used to determine pKa.
Upper panel: pH-mediated ring opening
of the intramolecular sprirolactam
of Gd.L2, yielding a highly fluorescent species. Lower
panels: (a) pH-dependent emission spectra of Gd.L2 (λex = 560 nm, λem = 580 nm); (b) pH titration
curve used to determine pKa.A titration curve was produced by plotting the
emission intensity
at λem = 580 nm versus pH, which yielded a pKa value of 5.11. It was hypothesized that the
change in the charge of Gd.L2 on going from pH ∼
7.0 to 4.0 would aid the probe to localize in the more acidic microenvironment
of tumor cells.[57] It has been shown that
the microenvironment of tumor cells is more acidic than that of healthy
tissues (Warburg effect). Upon entering an acidic environment, the
probe can undergo rearrangement to its ring-opened form, which is
fluorescent. This cationic acid form of the probe would then be expected
to accumulate in the mitochondria.[59]
In Vitro/in Vivo Studies
To test the viability of Gd.L2 as a dual-modal agent for cancer imaging, in vivo and
in vitro studies were carried out. Because of a lack of water solubility,
no in vivo studies could be carried out on L1 complexes.
The addition of an extra amide functionality within L2 introduced water solubility, and this allowed for the investigation
of its biological properties via in vitro and in vivo studies. Cell
penetration is crucial for the use of imaging probes in the monitoring
of biological mechanisms. To this end, preliminary in vitro cell studies
were carried out using Gd.L2. Rhodamine has been widely
used to determine the mitochondrial potential in tumor cells.[9] The negative mitochondrial potential is reported
to be greater in tumor cells than in normal cells, and organic cations
such as rhodamine have been shown to accumulate in the energized mitochondria.[59,60] With this in mind, colocalization experiments were undertaken wherein
a known mitochondrial stain (MitoTracker Green FM) was tested against Gd.L2. Confocal microscopy images of humanembryonic kidney
(HEK293) cells and primary mouse islet cells (∼70% insulin-containing
β cells) were recorded after a 30 min incubation with Gd.L2 and MitoTracker Green (Figure 6).
Figure 6
(A–C) Confocal microscopy images of HEK cells. Cells were
incubated with 215 mM Gd.L2 and 100 nM MitoTracker Green
for 30 min, washed twice with KREBS buffer, and visualized under a
fluorescence microscope. (A) MitoTracker Green signal. (B) Gd.L2 signal. (C) Merged signals. Scale bar: 50 μm. (D–F)
Confocal microscopy images of dissociated primary mouse islet cells.
Cells were incubated with 215 mM Gd.L2 and 100 nM MitoTracker
Green for 30 min, washed twice with KREBS buffer, and visualized under
a fluorescence microscope. (D) MitoTracker Green signal. (E) Gd.L2 signal. (F) Merged signals. Scale bar: 50 μm.
(A–C) Confocal microscopy images of HEK cells. Cells were
incubated with 215 mM Gd.L2 and 100 nM MitoTracker Green
for 30 min, washed twice with KREBS buffer, and visualized under a
fluorescence microscope. (A) MitoTracker Green signal. (B) Gd.L2 signal. (C) Merged signals. Scale bar: 50 μm. (D–F)
Confocal microscopy images of dissociated primary mouse islet cells.
Cells were incubated with 215 mM Gd.L2 and 100 nM MitoTracker
Green for 30 min, washed twice with KREBS buffer, and visualized under
a fluorescence microscope. (D) MitoTracker Green signal. (E) Gd.L2 signal. (F) Merged signals. Scale bar: 50 μm.Images B, C and E, F in Figure 6 show clear
accumulation of Gd.L2 within each cell type. However,
a clear colocalization of Gd.L2 and MitoTracker was not
evident (Figure 6C, box). Moreover, we noted
that in cells where significant uptake of Gd.L2 was apparent
(as indicated in the primary cells in D–F), MitoTracker accumulation
was lower and more diffuse than in neighboring cells, and little,
if any, colocalization of red and green staining was evident (Figure 6F). These findings are probably best explained by
the fact that the Gd.L2 fluorescence, which is strongly
suppressed at pH >6.5 (Figure 5B), is only
readily detectable in cells in which mitochondria are relatively depolarized,
such that the mitochondrial matrix pH falls to levels permissive of Gd.L2 fluorescence. Such mitochondria, however, are expected
to be poorly able to retain MitoTracker, whose accumulation depends
on the inner mitochondrial membrane potential and the pH gradient
(i.e., high intramitochondrial pH >7). These results are thus consistent
with the known properties of both MitoTracker and Gd.L2 but are unable to definitively establish a mitochondrial localization
of the latter.BALB/c nude mice with neck M21 (human melanoma
cell) xenograft
implantations were injected intravenously with 0.1 mmol kg–1Gd.L2. The mice were imaged in a 4.7 T MRI instrument
at different times (preinjection, 30 min post injection, and 60 min
post injection) to evaluate the effect of the contrast agent. Thirty
minutes after the injection of Gd.L2, a 36.5% decrease
in tumor average T1 was observed compared
with the baseline of the preinjection image (Figure 7a,b). This decrease in longitudinal relaxation time was retained
at least up to 60 min (31.3% decrease; Figure 7c). These preliminary images demonstrate that Gd.L2 functions
successfully in vivo by shortening the T1 of protons in the tumor sufficiently so as to give a more detailed
image. The observed accumulation of Gd.L2 in the tumor
area is consistent with the predicted effect of a lower pH environment
on the probe; the rearrangement of the lactam ring at acidic pH introduces
a positive charge in the molecule that can promote the intracellular
uptake of the molecule responsible of the average T1 decrease observed in the tumor.
Figure 7
Parametric T1 maps of a BALB/c nude
mouse tumor: (a) preinjection; (b) 30 min post injection with Gd.L2; (c) 60 min post injection with Gd.L2.
Scale bars in ms.
Parametric T1 maps of a BALB/c nude
mousetumor: (a) preinjection; (b) 30 min post injection with Gd.L2; (c) 60 min post injection with Gd.L2.
Scale bars in ms.
Conclusions
We
have reported the preparation and full characterization of two
rhodamine–DO3A conjugate derivatives. The DO3A units have been
coordinated to paramagnetic Gd(III) and luminescent Tb(III) centers.
Complexation with Tb(III) gives dual-luminescent probes with two different
time scales, and photophysical data collected also show the impact
of distance of the sensitizer and linker design from the lanthanidemetal center on the efficiency of energy transfer. When complexed
with Gd(III), they form dual-modal MRI/fluorescent probes. Ln.L2 is water-soluble and suitable for in vitro/in vivo studies, and Gd.L2 has r1 = 3.84 mM–1 s–1 (9.4 T, 25 °C) and has been shown to
be viable both in vitro and in vivo. The pH sensitivity of the probe
means that it functions as an “off–on” luminescent
probe that is sensitive to the small pH changes within cells. By coexpression
with a known mitochondrial stain, the probe has been hypothesized
to localize in the mitochondria of HEK cells. These studies demonstrate
that the probe is cell-penetrating, has a pH sensitivity to acidic
microenvironments, and is a tumor specific, dual-modal MRI/fluorescent
contrast agent.
Experimental Section
Materials
and Conditions
No special precautions were
taken to exclude air or moisture during reactions or workups, unless
otherwise stated. Products 2(61) and 4(62) were prepared via
literature methods from commercially available starting materials.
All other materials were purchased from commercial suppliers and used
without further purification.
Instrumentation
1H and 13C{1H} NMR spectra were
recorded at ambient temperature on a Bruker
400 MHz spectrometer and internally referenced to the residual solvent
peaks of CDCl3 at 7.26 ppm (1H) and 77.16 ppm
(13C{1H}) or MeOD at 3.31 ppm (1H)
and 49.15 ppm (13C{1H}). 13C{1H} spectra were fully assigned where possible using 2D correlation
spectroscopy. Mass spectrometry analyses were conducted by the Mass
Spectrometry Service, Imperial College London. Microanalyses were
carried out by Stephen Boyer of the Science Centre, London Metropolitan
University. ICP-MS analysis was carried out by Stanislav Strekopytov
of the Natural History Museum.
Fluorescence Measurements
Absorption and fluorescence
spectra of all complexes in either aqueous or methanolic solutions
depending on solubility were obtained at room temperature on a PerkinElmer
Lambda 25 spectrometer and a Cary Varian luminescence spectrometer
(using SCAN for Windows), respectively. Samples were held in 10 mm
× 4 mm quartz Hellma cuvettes. Lifetimes were measured by direct
excitation of the sample at 325 nm with a 40 ms pulse of light (50
pulses per point) followed by monitoring of the integrated intensity
of light emitted at 545 nm during a fixed gate time of 0.1 ms at a
delay time later. Delay times were set at 0.1 ms, covering four or
more lifetimes. Excitation and emission slits were set to 10:10 nm
bandpass respectively. The obtained decay curves were fitted to a
simple monoexponential first-order decay curve using Microsoft Excel.
Fluoresence quantum yields of terbium complexes were determined from
the integrated fluorescence intensities of the complexes following
a previously reported method[63] using the
reference compound[64] Na3[Tb(dpa)3] in water or methanol at 279 nm (quantum yield = 26.5% or
18.2%, respectively).A 1.49 mM solution
of Gd.L2 in 0.1 M NaCl (1 mL) was prepared, from which
15 × 67 μL
aliquots (microlitre pipet, Eppendorf) were taken. Each aliquot was
adjusted to the required pH using a digital pH meter (Jenway 3510)
equipped with a glass electrode (Jenway 924005). The pH was monitored
and adjusted to acidic or basic conditions using small aliquots of
a 1 M HCl or 1 M NaOH solution, respectively. The pH was allowed to
stabilize. The solution was then added to a quartz cuvette for fluorescence
analysis. The fluorimeter was operated using an excitation slit width
of 10 nm and an emission slit width of 2.5 nm.
Relaxivity Measurements
Gd.L1 was dissolved
in a methanol/water (50:50) solvent mixture to give a solution of
concentration 5 mM. Gd.L2 was dissolved in water to give
a solution concentration of 5 mM. The resulting solutions were placed
in 1.7 mm diameter capillaries, which were sealed. The 1/T1 measurements were performed on a Bruker Avance 400 spectrometer
(400 MHz). These experiments were carried out a minimum of three times,
and the relaxivity results given are averages of all experiments.
The concentration of Gd(III) was checked by the chemical shift measurement
of HOD induced by magnetic susceptibility.[65]
HSA Relaxivity Titration
A 1.49 mM solution of Gd.L2 in 0.1 M NaCl (pH 7.4) was prepared, from which 10 ×
67 μL aliquots were taken. To each aliquot was added an aliquot
of a 2 mM solution of HSA (0.1 M NaCl, pH 7.4) to give 10 different
sample concentrations (0, 0.1, 0.25, 0.35, 0.5, 0.65, 0.85, 1, 1.5,
and 2 equiv of HSA). The solutions were made up to a volume of 100
μL by addition of water where required. The resulting solutions
were placed in 1.7 mm diameter capillaries, which were sealed. The
1/T1 measurements were performed on a
Bruker Avance 400 spectrometer (400 MHz).
In Vivo Tumor Models
All of the animal experiments
were performed by licensed investigators in accordance with the United
Kingdom Home Office Guidance on the Operation of the Animal (Scientific
Procedures) Act 1986 and in keeping with the newly published guidelines
for the welfare and use of animals in cancer research.[66] Female BALB/c nude mice (aged 6–8 weeks;
Harlan) were used. M21 cells were injected subcutaneously on the back
of mice (5 × 106 cells in 100 μL of sterile
PBS). Animals were used when the xenografts reached ∼100 mm3. Tumor dimensions were measured continuously using calipers,
and tumor volumes (V) were calculated using the equation V = πabc/6, where a, b, and c represent the lengths
of the three orthogonal axes of the tumor.
In Vivo MRI
In
vivo MRI was performed in a 4.7 T horizontal-bore
DirectDrive MRI system (Varian, Palo Alto, CA, USA) equipped with
40 G/cm actively shielded gradients (VnmrJ 3.1). For imaging of the
tumors and generation of the T1 parametric
maps, a 45 mm diameter saddle coil was used in transmit mode and a
separate 20 mm diameter stripline resonator was used as a surface
coil to accommodate the tumors.[67] Imaging
was performed with an inversion recovery (IR) sequence and the following
parameters: axial images; FOV = 35 × 35 mm; No slices = 14; slice
thickness = 1 mm (zero slice gap); image bandwidth = 156 kHz; TR = 4500 ms; TI =
6, 14.6, 35.4, 86.1, 209, 508, 1230, or 3000 ms; NA = 2; image matrix
= 192 × 192; TA = 12 min. During imaging, animals were anesthetized
with 2% isofluorane and respiration and body temperature were monitored
via SA physiological monitoring systems (SA Instruments, Stony Brook,
NY, USA). Body temperature was monitored by a rectal probe and maintained
at 35 ± 1 °C. T1 maps were generated
in ImageJ[68] by fitting the acquired data
to the equation S = S0[1 – 2 exp(−TI/T1)], where TI is
the inversion time and T1 is the longitudinal
relaxation time. In order to assign the signal with the appropriate
sign for the fitting process, the χ2 value of the
fit was evaluated during the fitting. ROIs were then drawn on the T1 maps to delineate the whole tumor with consideration
to avoid the edges of the tumor and thus contamination from neighboring
tissues and partial volume effects.
In Vitro Cell Culture and
Imaging
HEK293 cells were
cultured in DMEM (Lonza) supplemented with 10% fetal bovine serum
(FBS) (Lonza), 1% glutamine (Lonza), and 1% penicillin/streptomycin
(Gibco). On the day of visualization, cells were washed twice with
KREBS buffer (140 mM NaCl, 3.6 mM KCl, 0.5 mM NaH2PO4, 0.2 mM MgSO4, 1.5 mM CaCl2, 10 mM
HEPES, pH 7.4, 2 mM NaHCO3) pre-equilibrated with 95:5
O2/CO2 and containing 25 mM glucose. Cells were
then incubated with KREBS buffer containing 215 mM Gd.L2 and 100 nM MitoTracker Green for 30 min and washed twice with KREBS
buffer before visualization. Images were captured using a Zeiss Axiovert
confocal microscope coupled to a Nipkow spinning-disk head (Yokogawa
CSU-10) using a 63× oil objective. A solid-state laser (CrystaLaser)
controlled by a laser-merge module (Spectral Applied Physics) provided
wavelengths of 491 nm to excite MitoTracker Green (emission filtered
at 525 nm) and 561 nm to excite Gd.L2 (emission filtered
at 620 nm). Images were captured by a highly sensitive 16-bit, 512
× 512 pixel back-illuminated EM-CCD camera (ImageEM 9100-13,
Hamamatsu). Volocity software (PerkinElmer) provided the user interface.
In Vivo Tissue Isolation and Imaging
Islet isolation
was carried out as shown in ref (69). In short, a female CD1mouse (8–12 weeks
old) was sacrificed by cervical dislocation. The pancreas was injected
with 1 mg/mL collagenase solution through the bile duct and excised.
The pancreas was digested by heating with collagenase solution, and
islets were isolated through the use of ficoll gradient centrifugation.
Islets were hand-picked and kept at 37 °C in Islet medium (RPMI
supplemented with 10% FBS and 1% penicillin/streptomycin). Islets
were dispersed into clusters and single cells according to the procedure
in ref (69). Briefly,
islets were incubated with Hank’s based enzyme-free dissociation
buffer (Invitrogen, Paisley, UK) and centrifuged. All but 1 mL of
the supernatant was removed, and the pellet was resuspended vigorously
via pipetting. The cells were washed and resuspended with RPMI 1640
and then loaded onto a poly-l-lysine-treated coverslip. On
the day of visualization, cells were washed twice with KREBS buffer
(140 mM NaCl, 3.6 mM KCl, 0.5 mM NaH2PO4, 0.2
mM MgSO4, 1.5 mM CaCl2, 10 mM HEPES, pH 7.4,
2 mM NaHCO3) pre-equilibrated with 95:5 O2/CO2 and containing 25 mM glucose. Cells were then incubated with
KREBS buffer containing 215 mM Gd.L2 and 100 nM MitoTracker
Green for 30 min and washed twice with KREBS buffer before visualization.
Images were captured using a Zeiss Axiovert confocal microscope coupled
to a Nipkow spinning-disk head (Yokogawa CSU-10) using a 63×
oil objective. A solid-state laser (CrystaLaser) controlled by a laser-merge
module (Spectral Applied Physics) provided wavelengths of 491 nm to
excite MitoTracker Green (emission filtered at 525 nm) and 561 nm
to excite Gd.L2 (emission filtered at 620 nm). Images
were captured by a highly sensitive 16-bit, 512 × 512 pixel back-illuminated
EM-CCD camera (ImageEM 9100-13, Hamamatsu). Volocity software (PerkinElmer)
provided the user interface.
Synthesis of 3
DO3A-t-Bu-ester (0.16 g, 0.28 mmol) and K2CO3 (0.05
g, 0.34 mmol) were dissolved in MeCN (5 mL), and the mixture was stirred
for 5 min. 2 (0.15 g, 0.28 mmol) in MeCN (15 mL) was
added dropwise. The reaction mixture was heated to reflux temperatures
for 24 h. The resulting solution was filtered, and the filtrate was
concentrated under reduced pressure. The crude product was purified
by silica gel chromatography with 1–20% MeOH/DCM, 1% NH3 solution (28%), affording 3 as a beige solid
(0.21 g, 37%). 1H NMR (400 MHz, CDCl3): δ
1.18 (t, 12H, 3JHH = 7.1 Hz),
1.43 (s, 27 H), 2.09–2.15 (m, 2H), 2.29–3.06 (m, 16H),
3.13–3.19 (m, 2H), 3.36 (q, 8H, 3JHH = 7.4 Hz), 3.50 (s, 6H), 6.23–6.43 (m, 6H),
7.04–7.08 (m, 1H), 7.41–7.47 (m, 2H), 7.81–7.84
(m, 1H). 13C NMR (100 MHz, CDCl3): δ 12.6,
28.0, 30.9, 36.0, 44.3, 46.2, 49.6, 51.0, 53.5, 55.8, 56.4, 65.2,
82.0, 82.4, 97.9, 105.1, 107.8, 122.6, 123.8, 128.0, 128.7, 131.0,
132.4, 148.8, 153.4, 153.5, 168.4, 172.5. ESI-HRMS: calcd for C56H83N7O8 982.6381, found m/z 982.6398.
Synthesis of L1
3 (0.20 g,
1 mmol) was dissolved in CH2Cl2 (2 mL), and
trifluoroacetic acid (2 mL) was added dropwise. The solution was stirred
at room temperature, open to air, for 24 h. The solvents were removed
in vacuo, and the residue was redissolved in CH2Cl2. This was repeated with diethyl ether and again with CH2Cl2 until L1 was obtained as a bright-pink
solid (0.16 g, 96%). 1H NMR (400 MHz, CDCl3):
δ 1.17 (t, 12H, 3JHH =
7.2 Hz), 3.06–3.71 (m, 24H), 4.20 (m, 2H), 6.54–6.75
(m, 6H), 7.14 (d, 1H), 7.60–7.64 (m, 2H), 7.80 (d, 1H). 13C NMR (100 MHz, CDCl3): δ 11.06, 34.14,
45.42, 45.63, 48.18, 49.33, 51.97, 52.26, 54.41, 110.36, 122.90, 124.22,
126.14, 128.62, 128.82, 129.83, 133.57, 153.00, 153.35, 160.78, 169.12.
ESI-HRMS: calcd for C44H60N7O8 814.4503, found m/z 814.4503.
Synthesis of Gd.L1
L1 (0.04
g, 0.05 mmol) and GdCl3·6H2O (0.01 g, 0.03
mmol) were dissolved in water (2 mL), and the pH was adjusted to 5.5
using 1 M NaOH solution. The mixture was stirred at room temperature
for 24 h. The reaction precipitate was filtered and then dissolved
in DCM. The organic layer was washed with water and then dried over
MgSO4. Addition of ether to this solution precipitated Gd.L1 as a pale-beige powder (0.022 g, 84%). ESI-HRMS: calcd
for C44H57N7O8Gd 969.3510,
found m/z 969.3569.
Synthesis
of Tb.L1
The complex was prepared
by an method analogous to that for Gd.L1 using L1 (0.26 g, 0.32 mmol) and TbCl3·6H2O (0.06 g, 0.16 mmol) to yield Tb.L1 as a pale-beige
solid (0.12 g, 80%). ESI-HRMS: calcd for C44H57N7O8Tb 970.3522, found m/z 970.3555.
Synthesis of 5
4 (0.50 g,
1.03 mmol) was dissolved in DCM (10 mL), and NEt3 (0.1
mL, 1.24 mmol) was added. The reaction mixture was cooled to 0 °C
using an ice bath, and chloroacetyl chloride (0.1 mL, 1.24 mmol) in
DCM (5 mL) was then added dropwise. The reaction mixture was allowed
to come to room temperature. The solution was stirred at room temperature
for 5 h, and then the solvent was removed under reduced pressure.
The resultant solid was dissolved in DCM (20 mL) and washed with water
(10 mL × 2) and brine. The organic extract was dried over MgSO4 and evaporated to give 5 as a purple solid (0.36
g, 62%). 1H NMR (400 MHz, CDCl3): δ 1.18
(t, 12H, 3JHH = 7.0 Hz), 3.10
(t, 2H, 3JHH = 7.1 Hz), 3.34
(q, 10H, 3JHH = 7.2 Hz), 3.95
(s, 2H), 6.31–6.47 (m, 6H), 7.08–7.11 (m, 1H), 7.46–7.48
(m, 2H), 7.93–7.96 (m, 1H). 13C NMR (100 MHz, CDCl3): δ 12.42, 39.50, 40.39, 41.43, 42.42, 45.01, 65.65,
98.87, 108.96, 123.08, 123.88, 128.41, 128.53, 130.22, 133.03, 148.26,
153.17, 153.55, 166.80, 169.46, 169.85. ESI-HRMS: calcd for C32H38ClN4O3 561.2632, found m/z 561.2646.
Synthesis of 6
Tri-tert-butyl-DO3A (0.32 g, 0.59 mmol)
and K2CO3 (0.08
g, 0.59 mmol) were dissolved in MeCN (20 mL) and left to stir for
5 min. 5 in MeCN (20 mL) was then added dropwise. The
reaction mixture was heated to reflux for 24 h. The resulting solution
was filtered, and the filtrate was concentrated under reduced pressure.
The crude product was purified by silica gel chromatography using
1–20% MeOH/DCM, 1% NH3 solution (33%), affording 6 as a beige solid (0.12 g, 21%). 1H NMR (400 MHz,
CDCl3): δ 1.18 (t, 12H, 3JHH = 7.0 Hz), 1.40 (s, 27H), 1.98–2.92 (m, 28H),
3.28 (q, 8H, 3JHH = 7.1 Hz),
6.24–6.41 (m, 6H), 7.01–7.04 (m, 1H), 7.35–7.45
(m, 2H), 7.76–7.83 (m, 1H). 13C NMR (100 MHz, CDCl3): δ 12.53, 27.86, 30.94, 40.00, 40.55, 44.31, 49.01,
50.27, 51.13, 55.66, 56.22, 65.43, 81.52, 97.68, 104.84, 108.17, 122.73,
123.84, 128.38, 130.05, 132.84, 148.8, 153.18, 169.63, 170.58, 171.01,
172.31. ESI-HRMS: calcd for C58H87N8O9 1039.6596, found m/z 1039.6676.
Synthesis of L2
6 (0.30 g,
0.3 mmol) was stirred in CH2Cl2 (1 mL), and
trifluoroacetic acid (1 mL, excess) was added dropwise. The solution
was stirred at room temperature, open to air, for 24 h. The solvents
were then removed in vacuo, and the residue was redissolved in CH2Cl2. This was again removed, and diethyl ether
was added. After removal of diethyl ether, this process was repeated,
affording L2 as a pink solid (0.23 g, 92%). 1H NMR (400 MHz, MeOD): δ 1.15 (t, 12H, 3JHH = 6.0 Hz), 2.84 (t, 2H, 3JHH = 7.0 Hz), 2.97–3.95 (m, 26H), 3.54
(q, 8H, 3JHH = 6.0 Hz), 6.60–6.66
(m, 6H), 7.11 (d, 1H), 7.59 (m, 2H), 7.90 (d, 1H). 13C
NMR (100 MHz, CDCl3): δ 10.88, 38.29, 39.01, 45.44,
46.52, 50.41, 53.10, 110.98, 115.25, 122.42, 123.66, 128.55, 128.91,
133.06, 153.05, 161.17, 161.51, 169.20. ESI-HRMS: calcd for C46H63N8O9 871.4702, found m/z 871.4718.
Synthesis of Gd.L2
L2 (0.19
g, 0.22 mmol) and GdCl3·6H2O (0.04 g, 0.11
mmol) were dissolved in water (2 mL), and the pH was adjusted to 5.5
using 1 M NaOH(aq). The reaction was left stirring at room temperature
overnight. The solution was removed in vacuo until a small volume
was left. This crude solution was purified using Sephadex G10 chromotography,
affording Gd.L2 as a pale-beige solid (0.03 g, 27%).
ESI-HRMS: calcd for C46H60GdN8O9 1026.3724, found m/z 1026.3834.
Synthesis of Tb.L2
The complex was prepared
by an method analogous to that for Gd.L2 using L2 (0.19 g, 0.21 mmol) and TbCl3·6H2O (0.04 g, 0.11 mmol) to yield Tb.L2 as a pale-beige
solid (0.03 g, 27%). ESI-HRMS (MeOH): calcd for C46H60N8O9Tb 1027.3737, found m/z 1027.3805.
Authors: Rakeshwar Bandichhor; Anca D Petrescu; Aude Vespa; Ann B Kier; Friedhelm Schroeder; Kevin Burgess Journal: Bioconjug Chem Date: 2006 Sep-Oct Impact factor: 4.774
Authors: M M Hüber; A B Staubli; K Kustedjo; M H Gray; J Shih; S E Fraser; R E Jacobs; T J Meade Journal: Bioconjug Chem Date: 1998 Mar-Apr Impact factor: 4.774
Authors: Victoria S R Harrison; Christiane E Carney; Keith W Macrenaris; Thomas J Meade Journal: Chem Commun (Camb) Date: 2014-10-09 Impact factor: 6.222
Authors: Son Long Ho; Hyunsil Cha; In Taek Oh; Ki-Hye Jung; Mi Hyun Kim; Yong Jin Lee; Xu Miao; Tirusew Tegafaw; Mohammad Yaseen Ahmad; Kwon Seok Chae; Yongmin Chang; Gang Ho Lee Journal: RSC Adv Date: 2018-04-03 Impact factor: 4.036
Authors: Didem Ag Seleci; Viktor Maurer; Firat Baris Barlas; Julian Cedric Porsiel; Bilal Temel; Elcin Ceylan; Suna Timur; Frank Stahl; Thomas Scheper; Georg Garnweitner Journal: Int J Mol Sci Date: 2021-04-27 Impact factor: 5.923
Authors: Victoria S R Harrison; Christiane E Carney; Keith W MacRenaris; Emily A Waters; Thomas J Meade Journal: J Am Chem Soc Date: 2015-07-14 Impact factor: 15.419
Authors: Sophie V Morse; Tamara Boltersdorf; Bethany I Harriss; Tiffany G Chan; Nicoleta Baxan; Hee Seok Jung; Antonios N Pouliopoulos; James J Choi; Nicholas J Long Journal: Theranostics Date: 2020-02-03 Impact factor: 11.556
Authors: Beatriz Brito; Thomas W Price; Juan Gallo; Manuel Bañobre-López; Graeme J Stasiuk Journal: Theranostics Date: 2021-08-07 Impact factor: 11.556